Table 1.
Summary of data from the three national product switches
| Study | Country | Switch to product | Population evaluated | Patients enrolled | Patients evaluated | Severe haemophilia A n (%) | Positive for inhibitors at baseline (preswitch) n (%) | Inhibitor detection (post-switch) n (%) |
|---|---|---|---|---|---|---|---|---|
| Bacon et al. 22 | Ireland | ADVATE® | Switchers | 113 | 113 | 101 (89) | 2 (1.7) | 1 (0.9) |
| Rubinger et al. 24 | Canada | Kogenate® | Switchers | 460 | 274 | 220 (89) | 4 (1.5) | 4 (1.5) |
| Hay et al. 23 | UK | ReFacto AF® | Switchers and non-switchers1 | 1217 | Switchers: 535 Non-switchers: 6822 |
1217 (100) | 0 | Switchers: 4 (0.75) Non-switchers: 1 (0.1)3 |
NA, not applicable.
1
One patient had previously documented inhibitors, and one child who had been on prophylaxis with Kogenate® developed an inhibitor during intense therapy for treatment of an acute bleed.
2
Patients remaining on Kogenate®.
3
The difference in inhibitor incidence rates between switchers and non-switchers was not significant (P = 0.12).